A prospective, open-label, randomized clinical trial to evaluate the efficacy and safety of remimazolam in patients undergoing EBUS-TBNA: REST trial design.

BMC Pulm Med

Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Respiratory Center, Yeungnam University Medical Center, 170 Hyeonchung-Ro, Namgu, Daegu, 42415, Republic of Korea.

Published: May 2024

AI Article Synopsis

  • - The REST trial aims to assess the safety and effectiveness of remimazolam for moderate sedation during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), comparing it against standard midazolam treatments.
  • - The study will enroll 330 patients with suspected lung cancer lesions across four university hospitals, randomly assigning them to receive either remimazolam or two types of midazolam for the procedure.
  • - Through this trial, researchers hope to establish improved sedation practices for EBUS-TBNA, potentially enhancing patient experiences and outcomes.

Article Abstract

Background: Remimazolam is safe and effective for moderate sedation during flexible bronchoscopy, but its safety and efficacy during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) remains undetermined. The REST trial (NCT06275594) will be a prospective randomized study of remimazolam in patients undergoing EBUS-TBNA with conscious sedation. The primary aim is to evaluate whether remimazolam is safe and effective for moderate sedation during EBUS-TBNA compared to real-world midazolam and on-label midazolam.

Methods: The REST trial will recruit 330 patients from four university hospitals with mediastinal lesions suspected of being lung cancer who are eligible for EBUS-TBNA under moderate sedation. The participants will be randomized into groups using remimazolam, real-world midazolam, and on-label midazolam (US prescribing information dosage) to perform EBUS-TBNA for procedural sedation. The primary endpoint will be procedural success using composite measures.

Discussion: The REST trial will prospectively evaluate the efficacy and safety of remimazolam during EBUS-TBNA under moderate sedation. It will provide information for optimizing sedation modalities and contribute to practical benefits in patients undergoing EBUS-TBNA.

Trial Registration: ClinicalTrials.gov (NCT06275594). Prospectively registered on 15 February 2024.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100028PMC
http://dx.doi.org/10.1186/s12890-024-03067-wDOI Listing

Publication Analysis

Top Keywords

rest trial
16
moderate sedation
16
patients undergoing
12
remimazolam patients
8
undergoing ebus-tbna
8
remimazolam safe
8
safe effective
8
effective moderate
8
real-world midazolam
8
midazolam on-label
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!